ライフサイエンスコーパス: GFR

1 GFR and body weight reduction were correlated.

2 GFR as estimated by GRAIL (hazard ratio [HR] 0.382, 95%

3 GFR decline leads to kidney failure, but regulators have

4 GFR reduction was larger in hyperfiltering (GFR >120 mL/

5 GFR was assessed in conscious TRPC6 wild type and knocko

6 rus (HCV) infection predicted early (year 1) GFR deterioration (area under the curve [AUC], 0.814).

7 The RO(2):GFR (ms/mL/min) was calculated as RO(2) (T2*, ms) divide

8 Whole-kidney RO(2):GFR was 25% lower in adolescents with T1D versus control

9 olescents with T1D, lower whole-kidney RO(2):GFR was associated with higher UACR (r = -0.31, P = 0.03

10 Lower medullary RO(2):GFR was associated with lower M/I (r = 0.31, P = 0.03).

11 There were 935 (22%) GFR measurements in persons who were healthy and 3274 (7

12 (3) GFR is evaluated using several methods available at the

13 n = 50) who had both early and late (year 5) GFR deterioration.

14 ple of both sexes, both the 97.5th and 2.5th GFR percentiles exhibited a negative linear association

15 95% confidence interval [CI]: 0.64 to 0.90; GFR <60 ml/min, 6.4% rivaroxaban plus aspirin, 8.4% aspi

16 tiple linear regression was used to derive a GFR equation.

17 eased urine albumin-to-creatinine ratio or a GFR below the threshold of 60 ml/min per 1.73 m(2) This

18 We subsequently developed and validated a GFR equation specifically for cirrhosis and compared the

19 he primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-mo

20 the LPAR antagonist BMS002 protects against GFR decline and attenuates development of DN through mul

21 Although GFR trajectories have been studied in several cohorts wi

22 60 mL/min/1.73 m; GFR between 30 and 60; and GFR <30.

23 ls can maintain overall renal blood flow and GFR stability despite severely impaired renal autoregula

24 d, and surface density of peripheral GBM and GFR decreased.

25 rrelations between serial protein levels and GFR over the first year.

26 tion by blood oxygen level-dependent MRI and GFR by iothalamate clearance.

27 ase (RVD) reduces renal blood flow (RBF) and GFR and accelerates poststenotic kidney (STK) tissue inj

28 end points were full clinical remission and GFR loss >/=15 ml/min per 1.73 m(2) during the 3-year tr

29 NO generation at the macula densa, TGF, and GFR in wild-type and macula densa-specific NOS1 knockout

30 ose had no effect on NO generation, TGF, and GFR.

31 Results Cr levels decreased and GFRs increased in both groups from before to after imagi

32 Serum Cr levels and GFRs for each time period were compared between groups b

33 on the rate of change in serum Cr levels and GFRs from before to after imaging.

34 variability of renal function was defined as GFR-VIM, which is variability independent of the mean (V

35 han for the general population, and falls as GFR declines.

36 However, as GFR declines, plasma oxalate (P(ox)) concentrations star

37 g younger persons, mortality is increased at GFR <75 ml/min per 1.73 m(2), whereas in elderly people

38 s included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate afte

39 The mean decrease in the iohexol-based GFR was -3.0 ml per minute per 1.73 m(2) per year with a

40 n-group difference in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m(2) (95% confidenc

41 The mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m(2) in the allopuri

42 es after additionally adjusting for baseline GFR.

43 However, tight linkage between GFR and proximal tubular secretory clearance in stable o

44 nd control littermates did not differ in BP, GFR, or natriuresis under baseline conditions.

45 was calculated as RO(2) (T2*, ms) divided by GFR (mL/min).

46 nd a dose-dependent drop in GFR, followed by GFR recovery within 4 weeks, that is, acute kidney disea

47 plus aspirin, irrespective of GFR category (GFR >=60 ml/min, 3.5% rivaroxaban plus aspirin, 4.5% asp

48 cirrhosis, the Royal Free Hospital cirrhosis GFR, using readily available variables; this remains to

49 a dedicated pharmacokinetic study to compare GFR with tubular secretory clearance for predicting kidn

50 llaboration (CKD-EPI) equations, we compared GFR estimated from creatinine (eGFRcreat), cystatin C (e

51 cal end point (doubling of serum creatinine, GFR<15 ml/min per 1.73 m(2), or ESKD) for each study.

52 wk, and in particular those with a decreased GFR, experience higher radiation exposure.

53 in Fabry disease-as well as with decreasing GFR.

54 her guidelines propose various age-dependent GFR thresholds with resulting profound differences in as

55 elines, including the approach to discordant GFR measurement and estimated GFR results, the use of me

56 ependent MRI; fat mass was estimated by DXA; GFR and RPF were estimated by iohexol and p-aminohippura

57 with G/G genotype had significantly lower e-GFR (107.5 +/- 20 versus 112.8 +/- 18 versus 125.3 +/- 2

58 s independently associated with both lower e-GFR (beta coefficient: -23.6; 95% confidence interval [C

59 The glomerular filtration rate (e-GFR) was estimated using the Bedside Schwartz equation,

60 n adducts are potential biomarkers for early GFR decline in T1DM and MA.

61 structural glomerular lesions, whereas early GFR decline may not accurately reflect such lesions.

62 transporter proteins in patients with early GFR decline is likely involved.

63 = 30) or new onset MA with and without early GFR decline (n = 22 and 33, respectively) for this study

64 (51)Cr-EDTA GFR was compared with the estimated GFR (eGFR) from seve

65 Cr) EDTA excretion measurements ((51)Cr-EDTA GFR) from white patients >/= 18 years of age with histol

66 ase with the onset of diabetes, and elevated GFR is a risk factor for the development of diabetic kid

67 ay serve as an alternative model to estimate GFR among patients with liver disease before and after L

68 dosing; however, the best method to estimate GFR in patients with cancer is unknown.

69 e used to develop a new equation to estimate GFR.

70 e with CKD G3a or G3b defined by 2 estimated GFR (eGFR) values more than 90 days apart were recruited

71 % [95% CI, 20.9% to 25.3%]) had an estimated GFR (eGFR) less than 45 mL/min/1.73 m2 and 699 (3.4%) we

72 a or 56 to 65 years of age with an estimated GFR of 25 to 44 ml per minute per 1.73 m(2) were randoml

73 ther 18 to 55 years of age with an estimated GFR of 25 to 65 ml per minute per 1.73 m(2) of body-surf

74 at least 4.5 mg per deciliter, an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m(2) of body-

75 to discordant GFR measurement and estimated GFR results, the use of method-specific GFR thresholds a

76 efore we concentrated on clinical (estimated GFR [eGFR], proteinuria, time posttransplant, donor-spec

77 high risk of CKD progression (eg, estimated GFR <30 mL/min/1.73 m2, albuminuria >=300 mg per 24 hour

78 stimated I-iothalamate GFR (iGFR), estimated GFR (eGFR), underestimated iGFR, and their average [Avg

79 end point was percentage change in estimated GFR (eGFR) trajectory over the treatment period.

80 years have seen major advances in estimated GFR (eGFR).

81 per 24 hours, or rapid decline in estimated GFR) should be promptly referred to a nephrologist.

82 The outcome was a composite of estimated GFR halving and graft loss.

83 ment with an exogenous tracer over estimated GFR, but only the British Transplant Society guidelines

84 s, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m(2)), a doubling of t

85 )Cr-EDTA GFR was compared with the estimated GFR (eGFR) from seven published models and our new model

86 ry end point was the change in the estimated GFR from baseline to follow-up, with adjustment for the

87 The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m(2) (95% confidenc

88 To determine this, we estimated GFR (eGFR) from serum creatinine measurements obtained f

89 Therefore, we estimated GFR in 18,015 individuals from the IMPROVE-IT (ezetimibe

90 els showed higher correlation with estimated GFR (eGFR) than UAER (r = - 0.23).

91 with commonly used equations for estimating GFR from SCr levels.

92 However, the method to evaluate GFR is still debated, and the thresholds of acceptable p

93 nce of the new derived formula with existing GFR formulae.

94 All guidelines favor GFR measurement with an exogenous tracer over estimated

95 loped and validated a new accurate model for GFR assessment in cirrhosis, the Royal Free Hospital cir

96 We developed a model for GFR assessment in liver disease (GRAIL) before and after

97 veloped a new multivariable linear model for GFR using statistical regression analysis.

98 m creatinine concentrations, and results for GFR from chromium-51 ((51)Cr) EDTA excretion measurement

99 ) may identify children with CKD at risk for GFR decline.

100 ition to include age-specific thresholds for GFR.

101 Similar findings were observed for GFRs.

102 rotected from kidney infarction but not from GFR loss because arterial obstructions persisted, identi

103 apy; P = 0.22); however, 3 patients now have GFR less than 20.

104 ammation attenuating CKD-progression (higher GFR and lower serum creatinine, proteinuria, kidney infl

105 lower (IQR, 7.3%-40.3%) than their pre-HSCT GFR.

106 GFR reduction was larger in hyperfiltering (GFR >120 mL/min) than nonhyperfiltering patients and was

107 ortive care or additional immunosuppression (GFR>/=60 ml/min per 1.73 m(2): 6-month corticosteroid mo

108 approved using differences in the change in GFR from the beginning to the end of a randomized, contr

109 trophy (P=0.003) at diagnosis and changes in GFR (P<0.001), peritubular capillaritis Banff score (P=0

110 otably the problem of implausible changes in GFR during the transition from adolescence to adulthood

111 isease labeling of an age-related decline in GFR is appropriate.

112 PAR inhibition also prevented the decline in GFR observed in vehicle-treated mice, such that GFR at w

113 Decline in GFR was not associated with changes in these morphometri

114 threefold in patients with early decline in GFR, compared to patients with stable GFR (0.0561 vs 0.0

115 ere higher in patients with early decline in GFR, compared to those with stable GFR.

116 with T1DM with and without early decline in GFR.

117 xploring the link to MA and early decline in GFR.

118 ous nephritis and the progressive decline in GFR.

119 Duration of hypothyroidism and a decrease in GFR less than 60 mL/min/1.73 m(2) significantly influenc

120 ent effects on GFR slope (mean difference in GFR slope between the randomized groups), for the total

121 arenal arteries and a dose-dependent drop in GFR, followed by GFR recovery within 4 weeks, that is, a

122 An absolute, supraphysiologic elevation in GFR is observed early in the natural history in 10%-67%

123 due to the nephrectomy-related reduction in GFR, followed by an age-related decline that may be more

124 s often leads to an accelerated reduction in GFR.

125 sis develop episodes of AKI and reduction in GFR; one-third progress to CKD, resulting in adverse out

126 TGF) response, thereby promoting the rise in GFR.

127 The dynamic ABMR prediction model included GFR (P<0.001) and presence of interstitial fibrosis/tubu

128 d new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring

129 r feedback from the macula densa to increase GFR.

130 BP through renal actions involving increased GFR and vascular and tubular effects.

131 ated with albuminuria and slightly increased GFR in meta-analyses of large population-based cohorts.C

132 The superimposition of Px and UNx increased GFR, indicating hyperfiltration.

133 hyperglycemia and glucosuria with increased GFR in mice.

134 oup guidelines advocates for age-independent GFR thresholds, most other guidelines propose various ag

135 ruct significantly attenuated Ang II-induced GFR decline in rats.

136 clearance (CrCl) overestimated I-iothalamate GFR (iGFR), estimated GFR (eGFR), underestimated iGFR, a

137 able indicator of overall kidney function is GFR, which is measured either via exogenous markers (eg,

138 Single-kidney GFR remained stable after MSC but fell in the medical tr

139 omparable reduction in measured whole-kidney GFR.

140 Last, GFR evaluation studies conducted in approved donors and

141 ith liver disease before and after LT at low GFR.

142 DRD-6 at time points before/after LT for low GFR.

143 Patients with proteinuria or lower GFR should be monitored more closely.

144 nts with proteinuria had significantly lower GFR (P = .005) but similar GFR during follow-up.

145 associated with preserved rather than lower GFR in some individuals.

146 ar filtration rate (GFR) >=60 mL/min/1.73 m; GFR between 30 and 60; and GFR <30.

147 Estimated mean GFR values at year 10 for belatacept 4-weekly, belatacep

148 althy aging is associated with a higher mean GFR compared with unhealthy aging.

149 Population mean GFR is lower in older age, but it is unknown whether hea

150 The mean GFR was 115+/-24 ml per minute, the mean number of nephr

151 The mean GFR was lower in older age by -0.72 ml/min per 1.73 m(2)

152 Measured GFR (mGFR) remains the reference standard, but the past

153 Measured GFR (mGFR) was performed at the same visit.

154 of this study include the lack of a measured GFR and the potential lack of ethnic diversity in the st

155 As expected, LSD did not alter measured GFR and increased the abundance of total and cell-surfac

156 n the other hand, HSD did not alter measured GFR but decreased the abundance of the aforementioned tr

157 graphy-tandem mass spectrometry and measured GFR by iohexol clearance (iGFR).

158 cross-sectional association between measured GFR, age, and health in persons aged 50-97 years in the

159 models (adjusted for demographics, measured GFR, proteinuria, body mass index, net endogenous acid p

160 nd placebo-treated groups in median measured GFR at 24 months (33 versus 42 ml/min per 1.73 m(2); P=0

161 The measured GFR (mGFR) by iothalamate clearance (n = 12,122, 1985-20

162 eGFR findings were confirmed using measured GFR.

163 Primary outcome was measured GFR (iohexol plasma clearance).

164 When measured GFR is unavailable, the Avg (CrCl and eGFR) provides a b

165 the initial evaluation of GFR, with measured GFR (mGFR) typically considered an important confirmator

166 73 m(2): 6-month corticosteroid monotherapy; GFR=30-59 ml/min per 1.73 m(2): cyclophosphamide for 3 m

167 tion of all nephrons, and the single-nephron GFR assesses the function of individual nephrons.

168 The single-nephron GFR did not vary significantly according to age (among d

169 How the single-nephron GFR relates to demographic and clinical characteristics

170 ,000 per kidney, and the mean single-nephron GFR was 80+/-40 nl per minute.

171 A higher single-nephron GFR was associated with a height of more than 190 cm, ob

172 A higher single-nephron GFR was associated with certain risk factors for chronic

173 The mean single-nephron GFR was calculated as the GFR divided by the number of n

174 lthy adult kidney donors, the single-nephron GFR was fairly constant with regard to age, sex, and hei

175 A higher single-nephron GFR was independently associated with larger nephrons on

176 ompensation (such as elevated single-nephron GFR) or kidney damage.

177 ings were correlated with the single-nephron GFR.

178 r age is there an increase in single-nephron GFR.

179 , albuminuria, and C reactive protein as non-GFR determinants of eGFRcys.

180 and all-cause mortality and investigated non-GFR determinants of eGFRcys.

181 t DNase I all prevented arterial occlusions, GFR loss, and kidney infarction.

182 depending on how accurate the assessment of GFR needs to be for application to the clinical, researc

183 recommend that cystatin-C-based estimates of GFR be used to confirm or exclude the diagnosis in peopl

184 Evaluation of GFR, required in the evaluation of living kidney donor c

185 ealth agencies for the initial evaluation of GFR, with measured GFR (mGFR) typically considered an im

186 ect serum creatinine levels independently of GFR, the earlier creatinine-based contraindication may h

187 aban 2.5 mg bd plus aspirin, irrespective of GFR category (GFR >=60 ml/min, 3.5% rivaroxaban plus asp

188 vival, defined as a composite of 50% loss of GFR that persisted for at least 1 month, the start of re

189 od evidence for cystatin C being a marker of GFR and risk in people with CKD, its use to define CKD i

190 he 6-year trial, with annual measurements of GFR (by urinary clearance of iothalamate) and ACR.

191 olescence to adulthood and overestimation of GFR in young adults.

192 The end point of GFR loss >/=15 ml/min per 1.73 m(2) did not differ betwe

193 the guideline recommendations, principles of GFR measurement and estimation, and our suggestions for

194 four groups (Q1-4) based on the quartiles of GFR-VIM, and the risks of incident AF by each group were

195 D risk in donors highlights the relevance of GFR assessment for living kidney donor candidates.

196 The primary end point was slope of GFR (DeltaGFR).

197 To assess the use of GFR slope as a surrogate end point for CKD progression,

198 We estimated treatment effects on GFR slope (mean difference in GFR slope between the rand

199 ribe the association of treatment effects on GFR slope with the clinical end point and to test how we

200 ion addresses these issues but overestimates GFR when SCr levels are low.

201 ese variables and the course of postdonation GFR.

202 the most accurate published model to predict GFR.

203 and the thresholds of acceptable predonation GFR vary across guidelines.

204 sed on good health, have a lower predonation GFR compared with younger donors.

205 Ambrisentan preserved GFR at the level of nondisease controls and prevented th

206 n Indians with type 2 diabetes and preserved GFR at baseline, increasing ACR reflects the progression

207 who had IgAN with relatively well preserved GFR and persistent proteinuria.

208 althy aging is not associated with preserved GFR in old age.

209 onth 3 after LT in recipients with preserved GFR who demonstrated subsequent GFR deterioration versus

210 travenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-spe

211 Neither immunosuppressive regimen prevented GFR loss, and both associated with substantial adverse e

212 rial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease featu

213 PUA, GFR (inulin), effective renal plasma flow (para-aminohip

214 The optimal modality for this purpose [GFR measurement by urinary Creatinine Clearance (uCrCl)

215 ith preoperative glomerular filtration rate (GFR) >=60 mL/min/1.73 m; GFR between 30 and 60; and GFR

216 iated with lower glomerular filtration rate (GFR) and higher blood pressure (BP) in patients with typ

217 ower predonation glomerular filtration rate (GFR) and increased ESKD risk in donors highlights the re

218 TRPC6 regulates glomerular filtration rate (GFR) and the contractile function of glomerular mesangia

219 Glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) are used

220 y measurement of glomerular filtration rate (GFR) and urine albumin excretion, and kidney injury was

221 The glomerular filtration rate (GFR) assesses the function of all nephrons, and the sing

222 Glomerular filtration rate (GFR) assessment is a key aspect in the evaluation of liv

223 Glomerular filtration rate (GFR) assessment is indicated before every administration

224 had an estimated glomerular filtration rate (GFR) at baseline of >=60 ml/min, 6,276 had a GRF of <60

225 ficant change in glomerular filtration rate (GFR) before or after therapy (64.2 +/- 16.5 mL/min per b

226 in the estimated glomerular filtration rate (GFR) but also caused more elevations in aminotransferase

227 for accelerated glomerular filtration rate (GFR) decline and nephropathy.

228 o predict future glomerular filtration rate (GFR) deterioration in this population.

229 decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-modera

230 Evaluation of glomerular filtration rate (GFR) is central to the assessment of kidney function in

231 Purpose The glomerular filtration rate (GFR) is essential for carboplatin chemotherapy dosing; h

232 nd rapid loss of glomerular filtration rate (GFR) is the predominant clinical feature of diabetic kid

233 Reduction in glomerular filtration rate (GFR) not meeting CKD criteria was observed in 66% of pat

234 had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m(2) of body-su

235 ification of the glomerular filtration rate (GFR) of individual kidneys in normal and pathological co

236 unction shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1.73 m(2), or markers of

237 Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes, and elev

238 The best glomerular filtration rate (GFR) recovery in survivors was a median 20% lower (IQR,

239 se to changes in glomerular filtration rate (GFR) to maintain glomerulotubular balance.

240 Glomerular filtration rate (GFR) was estimated using the GFR assessment in liver dis

241 ility (RO(2)) to glomerular filtration rate (GFR), a measure of relative renal hypoxia, in adolescent

242 , improvement in glomerular filtration rate (GFR), and reduced malignancy.

243 es, cholesterol, glomerular filtration rate (GFR), testosterone, androstenedione, and sex hormone bin

244 sed estimates of glomerular filtration rate (GFR), UK and international guidelines recommend that cys

245 versus decreased glomerular filtration rate (GFR).

246 s for estimating glomerular filtration rate (GFR).

247 ) and comparable Glomerular Filtration Rate (GFR).

248 ry end point was glomerular filtration rate (GFR).

249 or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria >=30 mg per 24 ho

250 Cr levels and glomerular filtration rates (GFRs) were grouped according to when they were obtained

251 reased urinary albumin excretion and reduced GFR in patients with diabetes, conservative dose selecti

252 d versus baseline), hypoalbuminemia, reduced GFR, and marked glomerular damage.

253 uation, with three recommendations regarding GFR.

254 hese results suggest that TRPC6 may regulate GFR by modulating MC contractile function through multip

255 gnificantly lower GFR (P = .005) but similar GFR during follow-up.

256 With large enough sample sizes, GFR slope may be a viable surrogate for clinical end poi

257 ated GFR results, the use of method-specific GFR thresholds and thresholds dependent on comorbidities

258 ine in GFR, compared to patients with stable GFR (0.0561 vs 0.0176 nmol/mg creatinine, P < 0.01).

259 ecline in GFR, compared to those with stable GFR.

260 e used a generalized additive model to study GFR distribution by age according to health status.

261 th preserved GFR who demonstrated subsequent GFR deterioration versus preservation by year 1 and year

262 sive review of the literature, we found that GFR declines with healthy aging without any overt signs

263 e outpatients provides some reassurance that GFR, even when estimated, is a useful surrogate for pred

264 observed in vehicle-treated mice, such that GFR at week 20 differed significantly between vehicle an

265 We suggest that GFR evaluation might be improved by more complete implem

266 ean single-nephron GFR was calculated as the GFR divided by the number of nephrons (calculated as the

267 (CrCl and eGFR)] essentially eliminated the GFR bias (median bias = +2.2, -5.4, and -1.0 mL/min/1.73

268 In type 1 diabetes, changes in the GFR and urine albumin-to-creatinine ratio (ACR) are rela

269 it is not clear whether small changes in the GFR slope will translate to clinical benefits.

270 ion of synthetic NPs similarly increased the GFR and renal perfusion in both genotypes.

271 r, both the mean and 97.5 percentiles of the GFR distribution are lower in older persons who are heal

272 and an iothalamate-based measurement of the GFR during donor evaluation and who underwent a kidney b

273 alpha-like (GFRAL), an orphan member of the GFR-alpha family, is a high-affinity receptor for GDF15.

274 rom numerous other studies indicate that the GFR threshold above which the risk of mortality is incre

275 iltration rate (GFR) was estimated using the GFR assessment in liver disease (GRAIL) developed among

276 clinical end point and to test how well the GFR slope predicts a treatment's effect on the clinical

277 made on the basis of factors in addition to GFR.

278 hese outcome events was inversely related to GFR.

279 tudies, the treatment effect on 3-year total GFR slope (median R (2)=0.97; 95% Bayesian credible inte

280 Incorporation of eGFR likely captures true GFR better than SCr, especially among women.

281 needed to develop a final assessment of true GFR.

282 are associated with error compared with true GFR.

283 (2) Two GFR thresholds are used for decision-making: a high thre

284 urinary Creatinine Clearance (uCrCl) versus GFR estimation (eGFR) by the CKD-EPI formula versus both

285 The predicted equation (r(2) = 74.6%) was GFR = 45.9 x (creatinine(-0.836) ) x (urea(-0.229) ) x (

286 increased urinary PGE(2) excretion, whereas GFR, plasma renin concentration, and urinary endothelin-

287 ress (FSS); however, it is not known whether GFR modulates PT endocytosis to enable maximally efficie

288 aluated in light of long-term risk, in which GFR is one of many factors.

289 uPAR, TNFR-1, and TNFR-2 are associated with GFR decline in children with CKD and in subgroups define

290 ta-2 microglobulin and CD40, correlated with GFR changes over the first year.

291 In patients with GFR >=60, the use of MAR versus SAR was associated with

292 h a difference in MACE amongst patients with GFR between 30 and 60 and better survival raises the pos

293 firm or exclude the diagnosis in people with GFR 45-59 ml/min/1.73 m2 and no albuminuria (CKD G3aA1).

294 care, the setting in which most people with GFR in this range are managed.

295 s aspirin versus aspirin alone in those with GFR >=60 ml/min (2.9% rivaroxaban plus aspirin, 1.6% asp

296 In those with GFR <30, MAR was not associated with a difference in out

297 I: 1.44 to 2.28) and similarly in those with GFR <60 ml/min (3.9% rivaroxaban plus aspirin, 2.7% aspi

298 In those with GFR between 30 and 60, MAR was not associated with a dif

299 ant stress are not associated with worsening GFR over time.

300 udy included diabetes duration (14.6 years), GFR (156 ml/min), and ACR (15 mg/g).